Khan Siddiqui - 23 May 2023 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role
Chief Medical Officer and Chief Strategy Officer
Signature
/s/ Brett Hale, Attorney-in-Fact
Issuer symbol
HYPR
Transactions as of
23 May 2023
Net transactions value
$0
Form type
4
Filing time
25 May 2023, 16:15:28 UTC
Previous filing
16 May 2023
Next filing
17 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HYPR Stock Option (right to buy) Award $0 +100,000 $0.000000 100,000 23 May 2023 Class A Common Stock 100,000 $1.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest as to 25% of the shares on May 23, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to Dr. Siddiqui's continued service through the applicable vesting date.

Remarks:

Chief Medical Officer and Chief Strategy Officer